Browse the evidence

Standard-of-care weight management in primary care is characterized by extremely low rates of active treatment, with only 12% of eligible patients receiving a weight-prioritized visit and less than 6% receiving any weight-related referral or anti-obesity drug prescription.

If you have a BMI over 25, do not assume your regular doctor is actively treating your weight. In standard practice, most patients like you are not getting referrals or medications. You must explicitly request a 'weight-prioritized visit' or ask for specific interventions (referrals, medications) to break through the system's inertia.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) do not increase the risk of thyroid or pancreatic cancer in humans, despite animal model concerns.

If you are prescribed a GLP-1 agonist like semaglutide or liraglutide, you do not need to worry about an increased risk of thyroid or pancreatic cancer based on current human data. The FDA warning is based on animal studies, and large human trials have not confirmed this risk.

Bariatric surgery reduces the overall incidence and mortality of cancer, with a more pronounced effect in women than men.

Bariatric surgery is a highly effective intervention for reducing the risk of cancer and cancer-related mortality in people with obesity. The benefit is particularly strong for women, likely due to the reduction in hormone-dependent cancers. The risk reduction is directly linked to the amount of weight lost.

Pharmacological inhibition or genetic deletion of the melanocortin-3 receptor (MC3R) enhances the anorectic and weight-loss efficacy of GLP-1 receptor agonists (e.g., liraglutide, semaglutide, tirzepatide) without increasing malaise or peripheral incretin effects.

Current research indicates that blocking the MC3R receptor can make GLP-1 weight loss drugs (like Ozempic or Wegovy) work better, allowing for lower doses to achieve the same weight loss. This happens without increasing the nausea or stomach upset often associated with these drugs. However, effective MC3R-blocking drugs that can cross into the brain are not yet widely available for human use.

MC3R inhibition generalizes to enhance sensitivity to other anorectic hormones, including leptin, peptide YY (PYY3-36), and cholecystokinin (CCK).

Blocking the MC3R receptor doesn't just help GLP-1 drugs; it may also make your body's natural satiety signals (like leptin and gut hormones) work more effectively. This suggests a broader benefit for appetite control beyond just one drug class.

High-sensitivity ELISA assays are required to detect exercise-induced reductions in fasting insulin, whereas standard automated immunoassays (e.g., Immulite 2000) fail to capture these changes despite high correlation with international standards.

If you are tracking insulin response to lifestyle changes (like exercise or diet), ensure your laboratory uses a high-sensitivity ELISA assay. Standard automated immunoassays may report 'normal' or unchanged insulin levels even when significant metabolic improvements have occurred, leading to a false conclusion that the intervention is ineffective.

Current clinical-metabolomic biomarkers (including BCAA and lipid profiles) cannot predict individual changes in insulin sensitivity following lifestyle interventions, despite their ability to correlate with baseline insulin levels.

Do not rely on current commercial metabolomic tests (like BCAA or detailed lipid panels) to predict whether you will lose weight or improve insulin sensitivity through exercise. These tests may tell you your current risk status, but they cannot tell you how your body will respond to a specific lifestyle change.

High consumption of artificially-sweetened beverages (ASBs) is not significantly associated with increased cardiovascular disease risk in physically active individuals.

If you are physically active, drinking two or more artificially-sweetened beverages a day does not appear to increase your cardiovascular disease risk in this study. However, this does not mean they are 'healthy,' and they should not be relied upon as a primary health strategy.

The enteric nervous system (ENS) directly senses luminal nutrients (glucose, fatty acids, amino acids) via specific receptors and ion channels on enteric neurons, independent of enteroendocrine cell intermediaries.

Your gut has its own nervous system that directly senses nutrients like glucose and fats, not just through hormones but through direct neural pathways. This 'second brain' communicates with your central brain to regulate hunger and satiety. Understanding this can help explain why certain foods trigger immediate physiological responses and why gut health is crucial for metabolic regulation.

GLP-1 release is significantly blunted or absent in morbidly obese individuals and those with type 2 diabetes, contributing to dysregulated nutrient sensing and appetite control.

In obesity and type 2 diabetes, the body's natural production of GLP-1, a hormone that helps you feel full, is often blunted. This makes it physiologically harder to regulate food intake. Treatments that mimic GLP-1 (like GLP-1 agonists) work by restoring this signal, highlighting the importance of this pathway in weight management.

Bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB), restores GLP-1 secretion by rapidly delivering nutrients to the distal gut where L-cells are concentrated, leading to increased satiety and weight loss.

Bariatric surgery, like RYGB, works partly by changing how your gut hormones respond to food. By delivering nutrients to the distal gut faster, it triggers a surge in GLP-1, a hormone that promotes satiety. This hormonal reset is a key factor in the weight loss achieved after surgery.

GLP-1 receptor agonists significantly delay gastric emptying and increase residual gastric content, but do not significantly increase the absolute risk of pulmonary aspiration in standard endoscopic procedures.

If you take GLP-1s (like Ozempic or Wegovy) for an endoscopy, expect your stomach to empty slower, but know the risk of lung infection is very low. You likely do not need to stop your medication unless you have specific symptoms or high-risk procedures. Follow extended clear-liquid fasting instructions and use gastric ultrasound if available to ensure safety.

GLP-1 receptor agonists impair colonic preparation and delay capsule transit, increasing the likelihood of inadequate bowel cleansing and the need for repeat colonoscopies.

If you take GLP-1s for a colonoscopy, your bowel prep might be less effective than usual. You may need a more intensive prep regimen (like extended clear liquids or additional laxatives) to ensure the doctor can see clearly. This is common and manageable.

Pharmacological inhibition of angiotensin-converting enzyme (ACE) using enalapril (20 mg/day) during 8 weeks of high-intensity training significantly attenuates exercise-induced increases in lean body mass in healthy adults, while peripheral muscle adaptations and aerobic performance remain unaffected.

If you are taking ACE inhibitors (like enalapril or lisinopril) for blood pressure, be aware that these medications may blunt your muscle growth potential compared to not taking them. This does not mean you cannot build strength or endurance, but your muscle mass gains may be reduced. Focus on consistent training and nutrition, and consult your doctor before making any medication changes.

The ACE I/D genotype is a poor predictor of actual ACE enzyme activity and downstream exercise adaptations because it is in linkage disequilibrium with functional variants and does not consistently correlate with circulating Angiotensin II levels.

Do not rely solely on genetic testing (like ACE I/D) to predict your athletic potential or training response. These tests are often poor predictors of actual performance or muscle growth. Instead, focus on consistent training, proper nutrition, and recovery. If you are curious about your biology, direct measurement of enzyme activity (phenotyping) is more informative than genetic markers alone.

Lifestyle interventions (caloric restriction and exercise) alone are ineffective for long-term obesity treatment because they trigger potent homeostatic adaptive responses (metabolic, hormonal, and appetitive) that defend a higher adipose mass set point and inevitably lead to weight regain.

Stop relying on willpower and calorie counting alone to cure obesity. Your body is biologically fighting to keep its weight at a higher 'set point' through hunger hormones and slowed metabolism. This is not your fault. To achieve lasting weight loss, you likely need medical or surgical interventions that override these biological defenses, as lifestyle changes alone will eventually trigger a rebound effect.

Lower drug prices for semaglutide and tirzepatide could significantly improve their cost-effectiveness, potentially making them competitive with surgical and behavioral interventions.

If drug prices for semaglutide and tirzepatide were reduced, these medications could become cost-effective options for managing class III obesity, potentially offering a non-surgical alternative.

Targeting enteroendocrine L-cells to stimulate endogenous release of GLP-1 and PYY is a viable therapeutic strategy for treating type 2 diabetes and obesity, leveraging the gut's spare hormonal capacity.

Current GLP-1 injections are effective, but research suggests that stimulating your gut's own hormone-producing cells (L-cells) using specific nutrients or future drugs could achieve similar benefits without injections. This involves targeting receptors for fats, amino acids, and bile acids in the intestine to boost natural GLP-1 and PYY release.

SGLT-2 inhibitors reduce cardiovascular and renal risks in type 2 diabetes patients by promoting glucose and sodium excretion, which triggers fatty acid beta-oxidation and depletes ectopic/visceral fat.

If you have Type 2 Diabetes and heart or kidney risks, ask your doctor about SGLT-2 inhibitors. These medications not only lower blood sugar but also help reduce harmful fat around your organs, which protects your heart and kidneys.

Energy-restricted diets have limited efficacy in reducing body fat and preventing cardiovascular events in T2DM compared to metabolic surgery or newer pharmacological interventions.

While healthy eating is crucial for T2DM, energy-restricted diets alone may not significantly reduce body fat or prevent heart problems in the long term. Combining diet with newer medications that target fat loss may be more effective.

Obesity severity (Class I, II, III) is directly correlated with increased direct medical costs, with Class III obesity costing up to 3.3 times more than normal weight individuals.

Higher obesity classes (II and III) are associated with significantly higher medical costs (up to 3.3x normal weight). This highlights the economic urgency of addressing obesity, especially in higher severity classes, through early intervention.

Intracerebroventricular administration of the GLP-1 receptor agonist Exendin-4(1-32)K-capric acid (Ex-4c) suppresses food intake and body weight gain in mice by directly activating arcuate pro-opiomelanocortin (POMC) neurons.

This research identifies that a specific GLP-1 agonist (Ex-4c) reduces food intake by directly activating POMC neurons in the hypothalamus. The mechanism involves the closure of KATP channels via PKA-dependent signaling. While this is preclinical data in mice, it supports the broader class of GLP-1 agonists used for obesity treatment by confirming a central neural mechanism involving appetite suppression.

Commercially available protein powders in the Hungarian market do not contain significant heavy metal contamination (lead, mercury, cadmium, arsenic) above regulatory safety limits.

If you buy protein powder from a reputable retailer in a regulated market (like the EU or USA), you do not need to worry about dangerous levels of heavy metals like lead or mercury. The products tested in this study were safe. However, because regulation is often voluntary, buying from unknown sources or unregulated 'grey markets' carries a higher risk of contamination.

Spinach thylakoid supplementation does not significantly improve renal function markers (urea, creatinine, total protein) in obese PCOS women compared to placebo, despite improvements in other metabolic indices.

Do not take spinach thylakoid extract expecting it to improve kidney function. While it helps with metabolic markers, this study showed no benefit for renal markers like urea or creatinine in obese PCOS women.